Ganymed Pharmaceuticals GmbH clinical trials
Acquired by Astellas Pharma Inc, Dec 20, 2016 · source ↗
The registry lists 3 studies whose lead sponsor is Ganymed Pharmaceuticals GmbH. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 13, 2025.
Before and after it joined Astellas Pharma Inc
- First submitted before Ganymed Pharmaceuticals GmbH became part of Astellas Pharma Inc
- 3
- First submitted after Ganymed Pharmaceuticals GmbH became part of Astellas Pharma Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Ganymed Pharmaceuticals GmbH3 studies
Something wrong with this grouping? Tell us on the Astellas Pharma Inc page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Astellas Pharma Inc studies →
- Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal CancerCompletedNCT01197885Phase 2
Sponsor listed in the registry: Ganymed Pharmaceuticals GmbH · First submitted before Ganymed Pharmaceuticals GmbH became part of Astellas Pharma Inc
- Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal CancerCompletedNCT00909025Phase 1
Sponsor listed in the registry: Ganymed Pharmaceuticals GmbH · First submitted before Ganymed Pharmaceuticals GmbH became part of Astellas Pharma Inc
- Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)CompletedNCT02054351Phase 1
Sponsor listed in the registry: Ganymed Pharmaceuticals GmbH · First submitted before Ganymed Pharmaceuticals GmbH became part of Astellas Pharma Inc